Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Advanz Pharma believes that Correvio's niche portfolio, consisting of an established brand, and two growing, patent-protected brands, plus a pipeline of potential product launches, are highly complementary to its current priorities and future focus.
Lead Product(s): Vernakalant Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Advanz Pharma
Deal Size: $76.0 million Upfront Cash: $76.0 million
Deal Type: Acquisition May 27, 2020
Details:
The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Lead Product(s): Tirofiban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hong Kong Teson Pharma
Deal Size: $3.5 million Upfront Cash: $3.0 million
Deal Type: Agreement March 10, 2020